New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by…